<DOC>
	<DOCNO>NCT02688933</DOCNO>
	<brief_summary>Primary Objective : To demonstrate morning injection Toujeo compare Lantus provide good glycemic control evaluate Continuous Glucose Monitoring ( CGM ) adult patient type 1 diabetes mellitus . Secondary Objective : To demonstrate treatment Toujeo compare Lantus provide : - Lower incidence rate nocturnal symptomatic hypoglycemia ; - Better glucose control coverage last hour CGM next basal-insulin dosing ; - Less variability CGM profile .</brief_summary>
	<brief_title>A Study Comparing Efficacy Safety Morning Injection Toujeo Versus Lantus Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>The maximum study duration per patient approximately 20 week consist 4-week screen training period include 1-2 week CGM performance ( allow re-training ) , 14-week open-label , comparative treatment period allow dose titration basal meal-time insulin , 1-2 week blind CGM collection fix dose Toujeo Lantus , 2 day post treatment follow-up period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Inclusion criterion : Adult patient ( male female ) type 1 diabetes mellitus ( T1DM ) . Signed write informed consent . Exclusion criterion : Age &lt; 18 year &gt; 70 year . Fasting cpeptide ≥0.3 nmol/L per source document central lab test Visit 1 . Glycated hemoglobin ( HbA1c ) ≤ 6.5 % ≥ 10.0 % via central lab test Visit 1 . Patients experience none episode document symptomatic and/or severe hypoglycemia ( per American Diabetes Association [ ADA ] classification ) past month prior screen . Patients experience &gt; 1 episode severe hypoglycemia result coma/seizures last 12 month screen . Patients receive less 1 year treatment basal plus mealtime insulin . Using basal insulin longacting insulin analog ( ie , Lantus , Toujeo , Levemir , Tresiba ) past 3 month screen . Requiring &gt; 80 U/day basal insulin analog stable dose ( ±20 % total dose ) within 30 day prior screen . Using few 2 injection rapidacting insulin analog per day within 30 day prior screen . Using human regular insulin mealtime insulin within 30 day prior screen . Using insulin pump last 6 month screen . History unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( e.g. , laser , surgical treatment , injectable drug ) study period . Pregnant breastfeed woman plan pregnancy duration study . Use investigational drug ( ) within 1 month 5 halflives , whichever long prior screening . Inappropriate CGM use screen period evidence failure obtain minimum 4 day usable record end screen . Noncompliance selfmonitored plasma glucose ( SMPG ) performance evidence failure demonstrate least 5 day 5 point SMPG record end screen . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>